ArticleMolecular neurobiology2025
Chamomile Modulates Glucose Metabolism and Neuro-inflammation to Alleviate Stress-Induced Depression in Mice.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression, a common psychiatric condition, is frequently associated with chronic stress. This research investigates the therapeutic benefit of chamomile (Matricaria chamomilla) against restraint stress (RS)-induced behavioral and neurobiological alterations in male mice. Animals were categorized into control, RS, and RS + chamomile (Cm) groups. Behavioral evaluation (open field, rotarod, catalepsy, memory test), histopathology, integrity of the blood-brain barrier, and gene expression profiling were done. In silico ProTox analysis confirmed the non-toxicity of chamomile compounds, including chamazulene, which also complies with Lipinski's Rule of Five, indicating drug-like properties. Molecular docking identified robust interactions between chamazulene and prominent stress-related and other relevant targets like IFN-γ, IL-6, caspase-3, BDNF, and GLUT-1. RS exposure interfered with locomotor activity, evoked neuroinflammation, apoptosis, and compromised neuronal-glial function. Treatment with chamomile greatly enhanced locomotor function and posture, decreased catalepsy latency test, and normalized neuronal architecture. Immunofluorescence staining and transcriptional analysis indicated that chamomile suppressed pro-inflammatory cytokines (IFN-γ, IL-6), the apoptotic marker Caspase-3, and increased neurotrophic and neuronal markers (BDNF, NeuN, GFAP) and glycolytic enzymes (GLUT-1, HK-1, LDHA). These results indicate that chamomile has neuroprotective actions by regulating RS-induced inflammation, apoptosis, and metabolic dysfunction. Although no remarkable effects were seen on body or brain-to-body weight ratio, chamomile exhibited powerful behavioral and molecular effects. Overall, the results highlight chamomile, particularly its active constituent chamazulene, as a promising candidate for alleviating restraint stress. However, further clinical validation is required to establish its therapeutic potential in neuropsychiatric disorders.
Indexed as
Identifiers
41351710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.